{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:37:46Z","timestamp":1777930666488,"version":"3.51.4"},"reference-count":9,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2017,1,8]],"date-time":"2017-01-08T00:00:00Z","timestamp":1483833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J VET Diagn Invest"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:p>Danofloxacin is a fluoroquinolone antibacterial agent approved for use in veterinary medicine to treat and control bovine respiratory disease caused by Mannheimia haemolytica or Pasteurella multocida. Susceptible minimal inhibitory concentration (MIC) breakpoint (\u22640.25 \u00b5g\/mL) and disk diffusion interpretive criteria (\u226522 mm) values for danofloxacin against M. haemolytica and P. multocida were first approved by the Clinical and Laboratory Standards Institute (CLSI) in 2003. However, intermediate and resistant breakpoint values were not established because only susceptible wild-type populations were evident at the time of breakpoint approvals. Since then, nonsusceptible isolates of M. haemolytica and P. multocida have been identified. We report danofloxacin intermediate MIC breakpoint (0.5 \u00b5g\/mL) and disk diffusion interpretive criteria (18\u201321 mm), as well as danofloxacin-resistant MIC breakpoint (\u22651 \u00b5g\/mL) and disk diffusion interpretive criteria (\u226417 mm), based on scattergram plots of MIC values versus disk zone diameters and calculated error-bound rates using M. haemolytica and P. multocida isolates recovered from bovine respiratory disease in North America in 2004\u20132014. These newly established intermediate and resistant clinical breakpoint values have been endorsed by CLSI and can be used for interpreting results from antibacterial susceptibility testing of danofloxacin against M. haemolytica and P. multocida isolated from bovine respiratory disease.<\/jats:p>","DOI":"10.1177\/1040638716683212","type":"journal-article","created":{"date-parts":[[2017,1,8]],"date-time":"2017-01-08T23:54:25Z","timestamp":1483919665000},"page":"224-227","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["New interpretive criteria for danofloxacin antibacterial susceptibility testing against\n                    <i>Mannheimia haemolytica<\/i>\n                    and\n                    <i>Pasteurella multocida<\/i>\n                    associated with bovine respiratory disease"],"prefix":"10.1177","volume":"29","author":[{"given":"Michael T.","family":"Sweeney","sequence":"first","affiliation":[{"name":"Zoetis Global Therapeutics Research, Kalamazoo, MI (Sweeney, Watts)"},{"name":"College of Veterinary Medicine, North Carolina State University, Raleigh, NC (Papich)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark G.","family":"Papich","sequence":"additional","affiliation":[{"name":"Zoetis Global Therapeutics Research, Kalamazoo, MI (Sweeney, Watts)"},{"name":"College of Veterinary Medicine, North Carolina State University, Raleigh, NC (Papich)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey L.","family":"Watts","sequence":"additional","affiliation":[{"name":"Zoetis Global Therapeutics Research, Kalamazoo, MI (Sweeney, Watts)"},{"name":"College of Veterinary Medicine, North Carolina State University, Raleigh, NC (Papich)."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2017,1,8]]},"reference":[{"key":"bibr1-1040638716683212","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Development of in vitro susceptibility testing criteria and quality control parameters for veterinary antimicrobial agents; approved guideline. 3rd ed. Wayne, PA: CLSI, 2008. CLSI document M37."},{"key":"bibr2-1040638716683212","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Performance standards for antibacterial disk and dilution susceptibility tests for bacteria isolated from animals; approved standard. 4th ed. Wayne, PA: CLSI, 2013. CLSI document VET01."},{"key":"bibr3-1040638716683212","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-1128(199609)16:5<433::AID-MED3>3.0.CO;2-W"},{"key":"bibr4-1040638716683212","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.2007.00896.x"},{"key":"bibr5-1040638716683212","doi-asserted-by":"publisher","DOI":"10.1086\/428052"},{"key":"bibr6-1040638716683212","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr406"},{"key":"bibr7-1040638716683212","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(06)70599-0"},{"key":"bibr8-1040638716683212","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00047-06"},{"key":"bibr9-1040638716683212","unstructured":"U.S. Food and Drug Administration (FDA). 2002. Freedom of Information Summary. Original new animal drug application, NADA 141-207. A180\u00ae sterile antimicrobial injectable solution (danofloxacin mesylate). Silver Springs, MD: FDA, 2002."}],"container-title":["Journal of Veterinary Diagnostic Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1040638716683212","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1040638716683212","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1040638716683212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:20:18Z","timestamp":1777681218000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1040638716683212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,8]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1177\/1040638716683212"],"URL":"https:\/\/doi.org\/10.1177\/1040638716683212","relation":{},"ISSN":["1040-6387","1943-4936"],"issn-type":[{"value":"1040-6387","type":"print"},{"value":"1943-4936","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,8]]}}}